Clinical Study Synopsis

Size: px
Start display at page:

Download "Clinical Study Synopsis"

Transcription

1 Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment. Healthcare Professionals should always refer to the specific labelling information approved for the patient's country or region. Data in this document or on the related website should not be considered as prescribing advice. The study listed may include approved and non-approved formulations or treatment regimens. Data may differ from published or presented data and are a reflection of the limited information provided here. The results from a single trial need to be considered in the context of the totality of the available clinical research results for a drug. The results from a single study may not reflect the overall results for a drug. The following information is the property of Bayer HealthCare AG. Reproduction of all or part of this report is strictly prohibited without prior written permission from Bayer HealthCare AG. Commercial use of the information is only possible with the written permission of the proprietor and is subject to a license fee. Please note that the General Conditions of Use and the Privacy Statement of bayerhealthcare.com apply to the contents of this file.

2 Webposting Clinical Trial Results Synopsis Study Sponsor: Bayer HealthCare AG Study Number: NCT Study Phase: IIIB Study Title: A prospective, randomized, double dummy, double blind, multi-center multinational trial comparing the efficacy and safety of moxifloxacin 400 mg PO QD 24 hours for 14 days to that of levofloxacin 500 mg PO QD 24 hours plus metronidazole 500 mg BID for 14 days in subjects with an uncomplicated pelvic inflammatory disease. Moxifloxacin, Metronidazole, and Levofloxacin in Asia (MONALISA Study) Therapeutic Area: Anti-Infective Name of Test Product: BAY / moxifloxacin HCl / Avelox Active Ingredient: Moxifloxacin, oral 400mg tablets Dosage: Moxifloxacin was administered orally 400 mg once daily (od) for 14 days. Ceftriaxone 250 mg was administered intramuscularly once at the During Therapy visit in subjects with a documented gonococcal infection. Reference Therapy: Oral levofloxacin 500 mg once daily (od) combined with oral metronidazole 500 mg twice daily (bid) Dosage: Levofloxacin 500 mg was administered as 2 x 250 mg tablets once daily (od) and metronidazole 500 mg was administered as one tablet twice daily (bid) for 14 days. Ceftriaxone 250 mg was administered intramuscularly once at the During Therapy visit in subjects with a documented gonococcal infection. Placebo: Not applicable Route of Administration: Oral ( moxifloxacin, levofloxacin and metronidazole); intramuscularly (ceftriaxone) Treatment Duration: The planned duration of the study was 6 to 8 weeks, including a 14 day treatment period and a 4- to 6-week (untreated) follow up period. Study Period: Date of first subjects first visit: 09 January 2007 Date of last subjects last visit 12 May 2008 Methodology: This was a multinational, multi-center, prospective, randomized, double-blind, phase IIIb study conducted using a parallel group design. Subjects matching eligibility criteria were assigned randomly to receive 14 days of treatment with either oral moxifloxacin 400 mg once daily or oral levofloxacin 500 mg once daily plus oral metronidazole 500 mg bid. One visit was planned during the treatment period (Day 4 to 7) to assess clinical progress. A single intramuscular injection of ceftriaxone 250 mg was administered at the During Therapy visit in all subjects with a documented gonococcal infection. Subjects were then followed until Day 28 to 42 after therapy with study medication was completed. Clinical, bacteriological, and laboratory examinations were performed pretreatment and at the test of cure (TOC) visit (7 to 14 days after last administration of study medication). In addition, all successfully treated subjects and subjects evaluated as indeterminate at TOC who did not receive additional antibiotic therapy had a follow-up evaluation 28 to 42 days after completion of study medication. Study Site: The study was conducted at 13 centers in 7 countries, including 6 centers in mainland China, 1 center in Indonesia, 1 center in South Korea, 1 center in the Philippines, 1 center in Pakistan, 1 center in Thailand, and 2 centers in Taiwan. Altogether, 463 subjects were enrolled.

3 Main Inclusion Criteria: Females aged 18 years or above Diagnosis of pelvic inflammatory disease (PID) based on all of the following symptoms Pelvic discomfort Direct lower abdominal tenderness with or without rebound tenderness Adnexal tenderness on bimanual vaginal examination Cervical motion tenderness on bimanual vaginal examination And one or more of the following signs: Rectal/tympanic/oral temperature value > 38.0 C or axillary temperature value > 37.5 C Elevated C-reactive protein (CRP) value (above the upper limit of normal [ULN] for the respective laboratory) White blood cell count (WBC) 10,500/mm3 Laparoscopic evidence of PID Signs suggestive of cervical infection, including mucopurulent cervical discharge or positive Gram stain for Gram-negative intracellular diplococci from the endocervix Untreated, recent (less than 14 days) documented gonococcal or chlamydial cervicitis Endocervical cultures and polymerase chain reaction (PCR) tests performed within 48 hours prior to start of therapy Willing to use condoms as barrier contraception until the completion of the TOC (or alternative antibiotic) visit Willing to have a physical examination at the different assessment visits Subjects who signed an informed consent form prior to study entry Study Objectives: Evaluation Criteria: Overall: The objectives of this study were to compare the efficacy and safety of oral moxifloxacin 400 mg administered once daily with those of oral levofloxacin 500 mg once daily plus oral metronidazole 500 mg twice daily in adult subjects with an uncomplicated PID. Efficacy (Primary): The primary efficacy variable was clinical response 7 to 14 days after the completion of study drug therapy (TOC visit). Efficacy (Secondary): Secondary efficacy parameters included the following: Clinical response on Treatment Day 4 to 7. Bacteriological response at the TOC visit. Clinical response at the TOC visit in subjects with a bacteriologically documented infection. Clinical and bacteriological responses at the Follow-up visit (28 to 42 days after the end of therapy). Necessity for modifying the antibiotic therapy for PID up to the TOC visit or for instituting an antibiotic therapy (for PID recurrence) from TOC up to the end of follow-up. Safety Evaluation of safety was based on adverse events, physical examinations including vital signs determination, and clinical laboratory tests

4 Statistical Methods: Efficacy (Primary): All statistical tests were 2-sided and performed at the 0.05 significance level. The primary efficacy variable was clinical response at the TOC visit, where failures from the During Therapy visit (Day 4 to 7) were carried forward (ie, successes were defined as subjects with clinical cure at TOC; failures were subjects with failure at the During Therapy visit or improvement or failure at TOC). For success rates, a 95% confidence interval (CI) of the difference between the two clinical success rates (moxifloxacin minus comparator group) was calculated using Mantel-Haenszel weights based on centers. If the lower limit of this 95% CI was greater than 15%, it was proven that treatment with moxifloxacin is clinically not less effective than the comparator treatment regimen. If the lower limit of this 95% CI was greater than 0, superiority of treatment with moxifloxacin was proven. Efficacy (Secondary): As secondary efficacy analyses, clinical response during treatment (4 to 7 days after start of treatment) and at the Follow-up visit (28 to 42 days post-therapy), and clinical response at the TOC visit in subjects with bacteriologically documented infection, were analyzed exploratively in the same way as the primary efficacy variable. In addition, bacteriological responses at the TOC and Follow-up visits were analyzed exploratively in the same way as the primary efficacy variable based on the subgroup of microbiologically valid subjects. At the TOC visit, persistence, presumed persistence, and superinfection were considered bacteriological failures. At the Follow-up visit, recurrence and reinfection were treated as bacteriological failures. A bacteriological success was defined as a subject with a bacteriological response classified as eradication or presumed eradication without occurrence of a superinfection. The correlation between clinical and bacteriological response was to be explored. Safety All analyses of safety endpoints were to be descriptive only; no formal testing was to be performed. All safety tabulations were to be produced for the ITT population (which is equivalent to the valid for safety population). Number of Subjects: A total of 460 randomized subjects (230 subjects/treatment arm) were planned (Revised per Amendment 2, dated 21 Dec 2007), with at least 200 subjects from mainland China. A total of 463 subjects were actually enrolled; 228 subjects were randomized into the moxifloxacin group and 232 into the levofloxacin/metronidazole group. Three subjects from mainland China were not randomized. Results Summary Subject Disposition and Baseline Figure 1 Subject Enrollment and Disposition 463 enrolled 460 randomized 412 completed treatment 399 completed study* Moxifloxacin 400 mg OD Levofloxacin 500 mg OD plus Metronidazole 500 mg BID 228 randomized 203 completed treatment 201 completed study* 232 randomized 209 completed treatment 198 completed study* 1 Subjects who had Follow-up assessment or alternative antibiotic assessment visit. Abbreviations: BID = twice daily; OD = once daily Source: Tables /1.1 and /2.1

5 Results Summary Efficacy The study demonstrated that a 14-day treatment with moxifloxacin 400 mg od is no less effective than a 14-day treatment with the comparator, levofloxacin 500 mg od plus metronidazole 500 mg bid, in adults with uncomplicated PID. Indeed, the lower limit of the 95% CI of the difference between the two clinical success rates (moxifloxacin minus comparator group) at the TOC visit was greater than 15%, see Table 2. Clinical Response Table 2 presents an overview of efficacy results (ie, success rates) for clinical response at TOC in the PP, ITT, and MBV populations. The success rate for clinical response at TOC in the PP population, the primary efficacy variable, was almost identical in the two treatment groups and the statistical hypothesis of inferiority of moxifloxacin to the comparator regimen could be rejected at the 2.5% level. Except for mainland China, sample sizes are too small to draw conclusion based on data from a single country. The results in mainland China were very much similar to those in subjects from all countries. The ITT clinical response results support the results from the per protocol analysis. Overall conclusions on the clinical response rates at the TOC visit in the microbiologically valid and ITT with causative organisms populations should be made with caution, since the number of subjects in this subgroup is small. The microbiologically valid population represents only 12.1% of the entire population. This subgroup is too small to allow for meaningful overall conclusions. Concerning the subgroup of subjects with microbiologically documented infection, the apparent difference in clinical cure rates between the two treatment groups is driven by an imbalance in subjects assessed as clinical improvements (scored as non-successes), ie, 9 in the moxifloxacin group versus 0 in the levofloxacin plus metronidazole group. The combined cure plus clinical improvement totals were 28/30 for moxifloxacin compared to 26/26 for levofloxacin plus metronidazole. Table 3 shows clinical resolution rates between the treatment groups in selected subject subgroups. No major differences between treatment groups in the clinical cure rates were observed. Results of the clinical efficacy analyses based on data for the ITT population generally were consistent with those in the PP population. Bacteriological Response The bacteriological success rates were high in both the moxifloxacin group (27/30=90%) and the comparator group (22/26=85%, 95% CI: -12.7% to 20.3%). The bacteriological success rates demonstrate that the apparent differences in clinical outcome between moxifloxacin and comparator in the microbiologically valid subjects are likely to be an artifact. Several factors may have contributed to the divergent clinical and bacteriological outcomes in this study. First, the small number of microbiologically evaluable subjects with pathogens at study entry (30 moxifloxacin subjects and 26 comparator subjects) limits the conclusions that can be drawn regarding bacteriological outcome. In addition, the difference between clinical and bacteriological success rates was driven mainly by high proportion of subjects with clinical improvement. In many cases, clinical improvement was associated with eradication, thus minimizing difference between the groups. Table 4 presents bacteriological successes at TOC by most frequently diagnosed organisms. In the MBV population, N. gonorrhoeae was diagnosed in 4 moxifloxacin subjects and 2 comparator subjects, and C. trachomatis was diagnosed in 8 moxifloxacin subjects and 12 comparator subjects. All 4 moxifloxacin subjects (100%) with N. gonorrhoeae and all 8 moxifloxacin subjects with C. trachomatis present at pre-therapy had an outcome of eradication at TOC. In the comparator group, 1 (50%) of the 2 subjects with N. gonorrhoeae and 10 of the 12 (83.3%) subjects with C. trachomatis present at pre-therapy had an outcome of eradication at TOC; the outcome in the other 3 subjects (1 [50%] with N. gonorrhoeae and 2 [16.7%] with C. trachomatis) was persistence. Overall, the number of individuals with diagnosed N. gonorrhoeae or C. trachomatis, was too low for meaningful comparisons or conclusions. Table 2: Overview of Efficacy Results (ie, Success Rates a ) for Clinical Response at TOC in the PP, microbiologically valid, ITT and ITT with causative organisms Populations Per Protocol Moxifloxacin Comparator 95% CI b n/n (%) n/n (%) Lower (%) Upper (%) Overall efficacy population 152/194 (78) 155/190 (82) Microbiologically valid China Mainland 110/138 (80) 102/128 (80) Indonesia 6/7 (86) 9/9 (100) Korea 8/11 (73) 7/11 (64) Philippines 10/13 (77) 13/15 (87) Pakistan 2/5 (40) 4/4 (100) Thailand 8/9 (89) 11/12 (92) China Taiwan 8/11 (73) 9/11 (82) Overall 19/30 (63) 26/26 (100) China Mainland 13/19 (68) 16/16 (100)

6 Table 2: Overview of Efficacy Results (ie, Success Rates a ) for Clinical Response at TOC in the PP, microbiologically valid, ITT and ITT with causative organisms Populations Valid for safety/intent to treat Moxifloxacin Comparator 95% CI b n/n (%) n/n (%) Lower (%) Upper (%) Indonesia 0/0 (0) 3/3 (100) Korea 0/1 (0) 0/0 (0) Philippines 3/6 (50) 5/5 (100) Thailand 2/3 (67) 2/2 (100) China Taiwan 1/1 (100) 0/0 (0) Overall 163/225 (72) 171/230 (74) China Mainland 113/151 (75) 111/155 (72) Indonesia 10/14 (71) 14/16 (88) Korea 8/12 (67) 8/13 (62) Philippines 10/15 (67) 13/15 (87) Pakistan 4/7 (57) 5/7 (71) Thailand 10/13 (77) 11/12 (92) China Taiwan 8/13 (62) 9/12 (75) Valid for safety/intent to treat with causative organisms Overall 23/36 (64) 30/34 (88) China Mainland 17/24 (71) 20/24 (83) Indonesia 0/1 (0) 3/3 (100) Korea 0/1 (0) 0/0 (0) Philippines 3/6 (50) 5/5 (100) Thailand 2/3 (67) 2/2 (100) China Taiwan 1/1 (100) 0/0 (0) a Success rate at TOC: No. of subjects with clinical response clinical cure / No. of subjects in population. b Hypothesis of inferiority of moxifloxacin rejected at the 2.5% level (ie, lower limit of CI > -15%) Source: Table /3.1, Table /3.2, Table /3.3, and Table /3.4 Table 3: Clinical Cure Rates at TOC in Selected Subject Subgroups (Per Protocol Population) Moxifloxacin Comparator (n = 194) (n=190) n/n a % n/n a % Overall resolution rate 152/194 (78%) 155/190 (82%) Age < 40 yrs 98/132 (74%) 111/135 (82%) > 40 yrs 54/62 (87%) 44/55 (80%) PID severity score /164 (78%) 125/155 (81%) /30 (80%) 30/35 (86%) Previous PID in the last 12 months None 102/133 (77%) 95/118 (81%) At least one episode 50/61 (82%) 60/72 (83%) Duration of symptoms Unknown 2/2 (100%) 3/3 (100%) before start of treatment 3 days 27/34 (79%) 36/40 (90%) > 3 days 123/158 (78%) 116/147 (79%) Condom use Sexual abstinence 38/48 (79%) 47/64 (73%) Only protected intercourse 113/140 (81%) 105/119 (88%) Unprotected intercourse 1/3 (33%) 3/6 (50%) Unknown 0/3 (0%) 0/1 (0%)

7 a No. of subjects with resolution in subgroup / total No. of subjects in subgroup Abbreviation: PID = pelvic inflammatory disease Source: Table /1.1.1, Table /1.2.1, Table /1.4.1, Table /1.5.1, and Table /1.7.1 Table 4: Bacteriological Success at TOC by Most Frequently Diagnosed Organisms (MBV Population) Overall Gram-positive aerobic Organism Moxifloxacin (n = 30) n/n a (%) Levofloxacin plus metronidazole (n = 26) n/n a (%) Staphylococcus aureus spp 3/3 (100) 3/4 (75) Gram-negative aerobic Neisseria gonorrhoeae 4/4 (100) 1/2 (50) Escherichia coli 6/7 (86) 2/2 (100) Proteus mirabilis 3/5 (60) 1/1 (100) Anaerobic organisms Peptostreptococcus spp 4/4 (100) 3/3 (100) Intracellular organisms Chlamydia trachomatis 8/8 (100) 10/12 (83) a No. of subjects with bacteriological success / No. of subjects with diagnosed organism Abbreviation: spp = species Source: Table /4.1 Results Summary Safety In the valid for safety population (moxifloxacin, 225 subjects; levofloxacin plus metronidazole, 230 subjects), treatment-emergent adverse events, and treatment-emergent drug-related adverse events were similar in the moxifloxacin and comparator groups (57% versus 57%, and 46% versus 49%, respectively). The 3 system organ classes in which the highest rates of adverse event occurred were gastrointestinal disorders (36% moxifloxacin versus 40% comparator); nervous system disorders (24% moxifloxacin versus 21% comparator); and general disorders and administration site conditions (8% moxifloxacin versus 6% comparator). The largest differences between treatment groups ( 2%) can be found in the SOC gastrointestinal disorders (36% moxifloxacin versus 40% comparator), nervous system disorders (24% moxifloxacin versus 21% comparator), general disorders and administration site conditions (8% moxifloxacin versus 6% comparator), psychiatric disorders (4% moxifloxacin versus 6% comparator), and cardiac disorders (1% moxifloxacin versus 3% comparator). The most commonly reported treatment-emergent adverse event in both the moxifloxacin (19% of subjects) and comparator (23% of subjects) treatment group was nausea. The only other adverse events reported in more than 5% of subjects in either treatment group were dizziness (reported in 17% and 16% of the moxifloxacin and comparator subjects), insomnia (reported in 3% and 6% of the moxifloxacin and comparator subjects), abdominal pain (reported in 4% and 6% of the moxifloxacin and comparator subjects) and vomiting (reported in 3% and 7% of the moxifloxacin and comparator subjects). No deaths were reported during the study. Four subjects experienced treatment-emergent serious adverse events, 3 moxifloxacin subjects and 1 comparator subject. Only one of the events, Stevens-Johnson syndrome, was considered drug related. This event occurred in a moxifloxacin-treated subject. Most adverse events reported in both treatment groups were mild or moderate in severity. Four subjects in the moxifloxacin group experienced adverse events of severe intensity, three in the comparator group. Of these, 3 events in each treatment group were considered drug related. Most adverse events resolved or had an improved outcome irrespective of whether they were assessed as drug related or not. Only 9 subjects in the moxifloxacin group reported an adverse event with outcome unchanged and none had an outcome of worsened. In the comparator group, 5 subjects experienced an adverse event that was unchanged and 2 had worsening as an outcome. The evaluation of significant changes of laboratory parameters did not reveal any relevant difference between treatments. No relevant treatment-related differences were detected in the analysis of vital signs. Conclusion(s) The results of the study provide evidence that moxifloxacin 400 mg PO od for 14 days is not clinically inferior in terms of clinical response rate to levofloxacin plus metronidazole for the treatment of uncomplicated PID. In addition, the safety profiles of moxifloxacin and of levofloxacin plus metronidazole regimens are similar.

8 Publication(s) Judlin P, Liao Q, Liu Z, Reimnitz P, Hampel B, Arvis P. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG Nov;117(12): doi: /j x. Epub 2010 Aug 18. Updated: 8 Nov 2012

9 Appendix to Clinical Study Synopsis Product Identification Information Product Type Drug US Brand/Trade Name(s) Avelox [Oral formulation] Brand/Trade Name(s) ex-us Generic Name Main Product Company Code Other Company Code(s) Chemical Description Other Product Aliases Avelox Avalox Actira Octegra Izilox Megaxin Proflox Promira Moxifloxacin BAY n/a 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro- 6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline- 3-carboxylic acid hydrochloride. n/a Date of last Update/Change: 11 September 2013

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Period of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)

Period of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit) Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's

More information

MANAGEMENT OF PELVIC INFLAMMATORY DISEASE

MANAGEMENT OF PELVIC INFLAMMATORY DISEASE GYNAECOLOGY SERVICES NORTH CUMBRIA MANAGEMENT OF PELVIC INFLAMMATORY DISEASE Author/Contact DOCUMENT CONTROL Lufti Shamsuddin, ST4 Obs & Gynae Trainee / Nalini Munjuluri, Consultant Gynaecology Tel: 01228

More information

moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering

moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007

Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007 Updated recommended treatment regimens for gonococcal infections and associated conditions United States, April 2007 1 Ongoing data from CDC 's Gonococcal Isolate Surveillance Project (GISP), including

More information

Tubo-ovarian abscess in OPAT

Tubo-ovarian abscess in OPAT Tubo-ovarian abscess in OPAT James Hatcher Consultant in Infectious Diseases and Medical Microbiology OUTLINE What is a tubo-ovarian abscess Current recommendations Our experience and challenges How to

More information

Reduce the risk of recurrence Clear bacterial infections fast and thoroughly

Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological

More information

Synopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets

Synopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Synopsis Name of the sponsor Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Name of active ingredient Title of the study Study

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)

More information

Simplicef is Used to Treat Animals with Skin Infections

Simplicef is Used to Treat Animals with Skin Infections Simplicef is Used to Treat Animals with Skin Infections PRODUCT INFO Simplicef tablets are a semi-synthetic cephalosporin antibiotic cefpodoxime proxetil used to cure infections caused by the susceptible

More information

Does flagyl treat gonorrhea and chlamydia

Does flagyl treat gonorrhea and chlamydia Does flagyl treat gonorrhea and chlamydia The Borg System is 100 % Does flagyl treat gonorrhea and chlamydia Mild Chlamydia infection, limited to the cervix, can be treated with a single dose of an antibiotic

More information

Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results. September 18, 2017

Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results. September 18, 2017 Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results September 18, 2017 Safe Harbor and Disclaimer Any statements in this presentation about future expectations, plans and prospects

More information

Université catholique de Louvain, Louvain Drug Research Institute, Brussels, Belgium. Bayer Santé SAS, Loos, France

Université catholique de Louvain, Louvain Drug Research Institute, Brussels, Belgium. Bayer Santé SAS, Loos, France Communicating Comprehensive Safety Data Gained from Clinical Trials to the Scientific Community: Opportunities and Difficulties from an Example with Moxifloxacin P.M. Tulkens, 1 P. Arvis, 2 F. Kruesmann,

More information

Critical Appraisal Topic. Antibiotic Duration in Acute Otitis Media in Children. Carissa Schatz, BSN, RN, FNP-s. University of Mary

Critical Appraisal Topic. Antibiotic Duration in Acute Otitis Media in Children. Carissa Schatz, BSN, RN, FNP-s. University of Mary Running head: ANTIBIOTIC DURATION IN AOM 1 Critical Appraisal Topic Antibiotic Duration in Acute Otitis Media in Children Carissa Schatz, BSN, RN, FNP-s University of Mary 2 Evidence-Based Practice: Critical

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.HNMC.04 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for important

More information

Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J

Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Record Status This is a critical abstract of an economic evaluation

More information

Bacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups

Bacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups Bacterial skin and soft tissues infections (SSTI) are one of the most common 1 infections among different age groups Gram-positive bacteria are the most frequently isolated pathogens from SSTI, with a

More information

Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis

Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis Steve SM Wong Alice Ho Miu Ling Nethersole Hospital Background PD peritonitis is a major cause of PD

More information

Lyme disease: diagnosis and management

Lyme disease: diagnosis and management National Institute for Health and Care Excellence Final Lyme disease: diagnosis and management [D] Evidence review for the management of erythema migrans NICE guideline 95 Evidence review April 2018 Final

More information

Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days

Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of

More information

Moxifloxacin (as hydrochloride) 400 mg Tablets WHOPAR part 6 November 2017 (Hetero Labs Limited), TB 315

Moxifloxacin (as hydrochloride) 400 mg Tablets WHOPAR part 6 November 2017 (Hetero Labs Limited), TB 315 This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

EPAR type II variation for Metacam

EPAR type II variation for Metacam 23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents

More information

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

Duration of antibiotic therapy:

Duration of antibiotic therapy: Duration of antibiotic therapy: How low can you go? Thomas Holland, MD Hilton Head, SC July 2017 Disclosures Consulting: The Medicines Company, Basilea Pharmaceutica Adjudication committee: Achaogen Grant

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY

More information

CLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met:

CLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met: CLINICAL PROTOCOL F COMMUNITY ACQUIRED PNEUMONIA SCOPE: Western Australia All criteria must be met: Inclusion Criteria Exclusion Criteria CB score equal or above 1. Mild/moderate pneumonia confirmed by

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Nuzyra) Reference Number: CP.PMN.## Effective Date: 11.20.18 Last Review Date: 02.19 Line of Business: Commercial, TBD HIM*, Medicaid Coding Implications Revision Log See Important Reminder

More information

Suitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)

Suitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP) STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.

More information

Guideline on the conduct of efficacy studies for intramammary products for use in cattle

Guideline on the conduct of efficacy studies for intramammary products for use in cattle 1 2 3 18 October 2013 EMEA/CVMP/EWP/141272/2011 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in cattle

More information

Clinical Policy: Clindamycin (Cleocin) Reference Number: CP.HNMC.08 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC

Clinical Policy: Clindamycin (Cleocin) Reference Number: CP.HNMC.08 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC Clinical Policy: (Cleocin) Reference Number: CP.HNMC.08 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy

More information

Srirupa Das, Associate Director, Medical Affairs, Tushar Fegade, Manager, Clinical Research Abbott Healthcare Private Limited, Mumbai.

Srirupa Das, Associate Director, Medical Affairs, Tushar Fegade, Manager, Clinical Research Abbott Healthcare Private Limited, Mumbai. Indian Medical Gazette JUNE 2015 225 Comparative A Randomized, Open Label, Prospective, Comparative Evaluating the Efficacy and Safety of Fixed Dose Combination of Cefpodoxime 200 Mg + Clavulanic Acid

More information

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Healthcare Associated

More information

April 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID

April 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID VOLUME FOUR; ISSUE 4 April 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID InPHARMation Pharmacy and Therapeutics Committee Update April 25 th, 2018 Meeting The Pharmacy and Therapeutics Committee

More information

Cephalosporins, Quinolones and Co-amoxiclav Prescribing Audit

Cephalosporins, Quinolones and Co-amoxiclav Prescribing Audit Cephalosporins, Quinolones and Co-amoxiclav Prescribing Audit Executive Summary Background Antibiotic resistance poses a significant threat to public health, as antibiotics underpin routine medical practice.

More information

THE VETERINARIAN'S CHOICE. Compendium clinical Trials. Introducing new MILPRO. from Virbac. Go pro. Go MILPRO..

THE VETERINARIAN'S CHOICE. Compendium clinical Trials. Introducing new MILPRO. from Virbac. Go pro. Go MILPRO.. THE VETERINARIAN'S CHOICE. Introducing new MILPRO from Virbac. Compendium clinical Trials Go pro. Go MILPRO.. milbemycin/praziquantel Content INTRODUCTION 05 I. EFFICACY STUDIES IN CATS 06 I.I. Efficacy

More information

General Approach to Infectious Diseases

General Approach to Infectious Diseases General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor

More information

Treating Rosacea in the Era of Bacterial Resistance. This presentation is sponsored by Galderma Laboratories, L.P.

Treating Rosacea in the Era of Bacterial Resistance. This presentation is sponsored by Galderma Laboratories, L.P. Treating Rosacea in the Era of Bacterial Resistance This presentation is sponsored by Galderma Laboratories, L.P. Lecture Discuss rosacea as an inflammatory condition Assess the psychosocial impact of

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:

More information

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS

More information

Study population The target population for the model were hospitalised patients with cellulitis.

Study population The target population for the model were hospitalised patients with cellulitis. Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals Vinken A G, Li J Z, Balan D A, Rittenhouse B E, Willke R J, Goodman C Record Status This is a

More information

B. PACKAGE LEAFLET 1

B. PACKAGE LEAFLET 1 B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Doxycycline Hyclate (Acticlate, Doryx), Doxycline (Oracea), Minocycline (Solodyn, Ximino) Reference Number: CP.CPA.120 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business:

More information

Infection Comments First Line Agents Penicillin Allergy History of multiresistant. line treatment: persist for >7 days they may be

Infection Comments First Line Agents Penicillin Allergy History of multiresistant. line treatment: persist for >7 days they may be Gastrointestinal Infections Infection Comments First Line Agents Penicillin Allergy History of multiresistant Campylobacter Antibiotics not recommended. Erythromycin 250mg PO 6 Alternative to first N/A

More information

Community Acquired Pneumonia: An Update on Guidelines

Community Acquired Pneumonia: An Update on Guidelines Community Acquired Pneumonia: An Update on Guidelines Claudia Summa, BScPhm Pharmacy Resident September 12, 2006 Objectives To give a brief description of the pathophysiology of community acquired pneumonia

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.HNMC.24 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for important

More information

November 2017 Review Nov Signatures of those developing the Patient Group Direction Job Title Name Signature Date Doctor Stephanie Dundas

November 2017 Review Nov Signatures of those developing the Patient Group Direction Job Title Name Signature Date Doctor Stephanie Dundas Supply of Trimethoprim 200mg tablets by Community Pharmacists for the Management of Uncomplicated Urinary Tract Infections in Female Patients from 16 and 65 years of age. November 2017 Review Nov 2019

More information

Drug Class Literature Scan: Otic Antibiotics

Drug Class Literature Scan: Otic Antibiotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects

More information

Public Assessment Report Paediatric data. EXOCIN (OCUFLOX) Ofloxacin. Marketing Autorisation Holder: Allergan

Public Assessment Report Paediatric data. EXOCIN (OCUFLOX) Ofloxacin. Marketing Autorisation Holder: Allergan Public Assessment Report Paediatric data EXOCIN (OCUFLOX) Ofloxacin Marketing Autorisation Holder: Allergan Rapporteur: Co-Rapporteur: Currently approved indication(s): Pharmaceutical form(s) and strengths

More information

Development of Drugs for HAP-VAP. Robert Fromtling, MD

Development of Drugs for HAP-VAP. Robert Fromtling, MD Development of Drugs for HAP-VAP Robert Fromtling, MD Hospital-Acquired & Ventilator- Associated Pneumonia (HAP-VAP) The EMA 2015 roadmap recognizes the need for new antibiotics New drugs for HAP-VAP are

More information

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes

More information

Intra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018

Intra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Intra-Abdominal Infections Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Select guidelines Mazuski JE, et al. The Surgical Infection

More information

Unasyn alternative if penicillin allergic

Unasyn alternative if penicillin allergic Unasyn alternative if penicillin allergic The following guidelines have been developed to assist physicians with the appropriate selection of prophylactic and empiric antibiotic therapy for potential and.

More information

SECTION 3A. Section 3A Criteria for Optional Special Authorization of Select Drug Products

SECTION 3A. Section 3A Criteria for Optional Special Authorization of Select Drug Products SECTION 3A Criteria for Optional Special Authorization of Select Drug Products Section 3A Criteria for Optional Special Authorization of Select Drug Products CRITERIA FOR OPTIONAL SPECIAL AUTHORIZATION

More information

AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES

AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES Update in Medicine and Primary Care Whitney R. Buckel, PharmD, BCPS-AQ ID System Antimicrobial Stewardship Pharmacist Manager OBJECTIVES 1. List three antibiotics

More information

UTI Dr S Mathijs Department of Pharmacology

UTI Dr S Mathijs Department of Pharmacology UTI Dr S Mathijs Department of Pharmacology Introduction Responsible for > 7 million consultations annually 15% of all antibiotic prescriptions 40% of all hospital acquired infections Significant burden

More information

17 th Club Phase 1 Annual Meeting April 5, Pierre Maison-Blanche Hopital Bichat, Paris, France

17 th Club Phase 1 Annual Meeting April 5, Pierre Maison-Blanche Hopital Bichat, Paris, France Practical Issues for the clinical evaluation of QT/QTc interval prolongation 17 th Club Phase 1 Annual Meeting April 5, 2018 Pierre Maison-Blanche Hopital Bichat, Paris, France Disclosure Chiesi Pharmaceuticals

More information

Short Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil

Short Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil Short Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil D. Adam, MD PhD, Munich, Germany H. Scholz, MD PhD, Berlin,

More information

Author - Dr. Josie Traub-Dargatz

Author - Dr. Josie Traub-Dargatz Author - Dr. Josie Traub-Dargatz Dr. Josie Traub-Dargatz is a professor of equine medicine at Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. She began her veterinary

More information

WHO Guideline for Management of Possible Serious Bacterial Infection (PSBI) in neonates and young infants where referral is not feasible

WHO Guideline for Management of Possible Serious Bacterial Infection (PSBI) in neonates and young infants where referral is not feasible WHO Guideline for Management of Possible Serious Bacterial Infection (PSBI) in neonates and young infants where referral is not feasible Department of Maternal, Newborn, Child & Adolescent Health Newborn

More information

Phase III Clinical Trial of Moxifloxacin Hydrochloride in the Treatment of Acute Exacerbations of Chronic Bronchitis in Comparison with Azithromycin

Phase III Clinical Trial of Moxifloxacin Hydrochloride in the Treatment of Acute Exacerbations of Chronic Bronchitis in Comparison with Azithromycin ORIGINAL ARTICLE JIACM 2002; 3(4): 360-6 Phase III Clinical Trial of Moxifloxacin Hydrochloride in the Treatment of Acute Exacerbations of Chronic Bronchitis in Comparison with Azithromycin SH Talib*,

More information

Study Protocol. Funding: German Center for Infection Research (TTU-HAARBI, Research Clinical Unit)

Study Protocol. Funding: German Center for Infection Research (TTU-HAARBI, Research Clinical Unit) Effectiveness of antibiotic stewardship interventions in reducing the rate of colonization and infections due to antibiotic resistant bacteria and Clostridium difficile in hospital patients a systematic

More information

Submission for Reclassification

Submission for Reclassification Submission for Reclassification Fucithalmic (Fusidic Acid 1% Eye Drops) From Prescription Medicine to Restricted Medicine (Pharmacist Only Medicine) CSL Biotherapies (NZ) Limited 666 Great South Road Penrose

More information

Mastitis in ewes: towards development of a prevention and treatment plan

Mastitis in ewes: towards development of a prevention and treatment plan SCHOOL OF LIFE SCIENCES, UNIVERSITY OF WARWICK Mastitis in ewes: towards development of a prevention and treatment plan Final Report Selene Huntley and Laura Green 1 Background to Project Mastitis is inflammation

More information

amoxycillin/clavulanate vs placebo in the prevention of infection after animal

amoxycillin/clavulanate vs placebo in the prevention of infection after animal Archives of Emergency Medicine, 1989, 6, 251-256 A comparative double blind study of amoxycillin/clavulanate vs placebo in the prevention of infection after animal bites P. H. BRAKENBURY & C. MUWANGA Accident

More information

Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)

Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory

More information

Study of First Line Antibiotics in Lower Respiratory Tract Infections in Children

Study of First Line Antibiotics in Lower Respiratory Tract Infections in Children IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) e-issn:2278-3008, p-issn:239-7676. Volume 2, Issue 4 Ver. VI (Jul Aug 207), PP 47-55 www.iosrjournals.org Study of First Line Antibiotics in

More information

Interventions for children with ear discharge occurring at least two weeks following grommet(ventilation tube) insertion(review)

Interventions for children with ear discharge occurring at least two weeks following grommet(ventilation tube) insertion(review) Cochrane Database of Systematic Reviews Interventions for children with ear discharge occurring at least two weeks following grommet(ventilation tube) insertion(review) Venekamp RP, Javed F, van Dongen

More information

Clinical Practice Standard

Clinical Practice Standard Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:

More information

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. BAYER HEALTHCARE LLC Animal Health Division USA Product Label http://www.vetdepot.com P.O. BOX 390, SHAWNEE MISSION, KS, 66201 0390 Customer Service Tel.: 800 633 3796 Customer Service Fax: 800 344 4219

More information

Delayed Prescribing for Minor Infections Resource Pack for Prescribers

Delayed Prescribing for Minor Infections Resource Pack for Prescribers Delayed Prescribing for Minor Infections Resource Pack for Prescribers Background: Antibiotic resistance is an alarming threat to modern healthcare, and infectious illness remains a major global threat

More information

Job Title Name Signature Date

Job Title Name Signature Date Supply of Trimethoprim 200mg tablets By Community Pharmacists for the Management of Uncomplicated Urinary Tract Infections in Female Patients Protocol number 473 Version 1 Date protocol prepared: November

More information

B. PACKAGE LEAFLET 1

B. PACKAGE LEAFLET 1 B. PACKAGE LEAFLET 1 PACKAGE LEAFLET FOR: Cadorex 300 mg/ml solution for injection for cattle, sheep and pigs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION

More information

Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)

Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of

More information

Women s Antimicrobial Guidelines Summary

Women s Antimicrobial Guidelines Summary Women s Antimicrobial Guidelines Summary 1. Introduction and Who Guideline applies to This guideline has been developed to deliver safe and appropriate empirical use of antibiotics for patients at University

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: Antibiotic treatment and monitoring for suspected or confirmed early-onset neonatal infection bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to

More information

Case 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance

Case 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance Case 2 Synergy satellite event: Good morning pharmacists! Case studies on antimicrobial resistance 22nd Congress of the EAHP "Hospital pharmacists catalysts for change", 22-24 March 2017, Cannes Disclosure

More information

choice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration*

choice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration* Virbac Dermatology Palatable Tablets The choice First generation cephalosporin for skin infections Now registered for ONCE daily administration* are only available under Veterinary Authorisation. www.virbac.co.nz

More information

Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017

Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t

More information

ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective

ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role

More information

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only USA Product Label http://www.vetdepot.com PHARMACIA & UPJOHN COMPANY Division of Pfizer Inc. Distributed by PFIZER INC. 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Fax: 616-833-4077 Customer

More information

THERAPY OF ANAEROBIC INFECTIONS LUNG ABSCESS BRAIN ABSCESS

THERAPY OF ANAEROBIC INFECTIONS LUNG ABSCESS BRAIN ABSCESS THERAPY OF ANAEROBIC INFECTIONS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu LUNG ABSCESS A lung abscess is a localized pus cavity in

More information

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 250 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PT, RO,

More information

Unshakeable confidence

Unshakeable confidence NEW PRODUCT OF THE YEAR as voted by vets for the 2nd year running** Unshakeable confidence Osurnia is the only otitis externa* treatment that applies like a liquid and stays like a gel. Right where you

More information

DOSAGE FORMS AND STRENGTHS Otic Suspension: Each OTIPRIO vial contains 1 ml of 6% (60 mg/ml) ciprofloxacin otic suspension. (3)

DOSAGE FORMS AND STRENGTHS Otic Suspension: Each OTIPRIO vial contains 1 ml of 6% (60 mg/ml) ciprofloxacin otic suspension. (3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTIPRIO safely and effectively. See full prescribing information for OTIPRIO. OTIPRIO (ciprofloxacin

More information

Scientific Discussion post-authorisation update for Rheumocam extension X/007

Scientific Discussion post-authorisation update for Rheumocam extension X/007 5 May 2011 EMA/170257/2011 Veterinary Medicines and Product Data Management Scientific Discussion post-authorisation update for Rheumocam extension X/007 Scope of extension: addition of 20 mg/ml solution

More information

Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children

Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Antimicrobials for Common Illnesses When treating common illnesses such as ear infections and strep throat,

More information

UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM

UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM Diane Rhee, Pharm.D. Associate Professor of Pharmacy Practice Roseman University of Health Sciences Chair, Valley Health

More information

ISMP Canada HYDROmorphone Knowledge Assessment Survey

ISMP Canada HYDROmorphone Knowledge Assessment Survey ISMP Canada HYDROmorphone Knowledge Assessment Survey Knowledge Assessment Questions 1. In an equipotent dose, HYDROmorphone is more potent than morphine. True False Unsure 2. HYDROmorphone can be given

More information

LINEE GUIDA: VALORI E LIMITI

LINEE GUIDA: VALORI E LIMITI Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 500 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Ophtocycline 10 mg/g eye ointment for dogs, cats and horses (AT, BE, BG, CY, CZ, EL, ES, HR, HU, IE, IT, LU, NL,

More information

Cipro for klebsiella uti

Cipro for klebsiella uti Cipro for klebsiella uti Search Can UTI be an effective treatment for Klebsiella Pneumoniae? It is safe or dangerous to use UTI while suffering from Klebsiella Pneumoniae? 87 discussions on Treato. instock

More information